Positive Media Coverage Somewhat Unlikely to Impact Tetralogic Pharmaceuticals Corp (TLOG) Stock Price
News stories about Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) have been trending positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tetralogic Pharmaceuticals Corp earned a news sentiment score of 0.37 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.0098148323858 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) traded down 3.1250% during mid-day trading on Tuesday, reaching $0.0155. The company’s stock had a trading volume of 1,000 shares. The firm’s market capitalization is $383919.50. Tetralogic Pharmaceuticals Corp has a 12 month low of $0.02 and a 12 month high of $0.25. The stock’s 50-day moving average is $0.02 and its 200-day moving average is $0.04.
About Tetralogic Pharmaceuticals Corp
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases.
Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.